期刊
CANCER LETTERS
卷 414, 期 -, 页码 214-221出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2017.11.020
关键词
Multiple myeloma; Signaling pathway; Targeting therapy
类别
资金
- National Natural Science Foundation of China [81400819, 81372538]
Multiple myeloma (MM), which is characterized by osteolytic bone lesions, anemia, hypercalcemia, and renal failure, accounts for approximately 10% of all hematologic malignancies. Although the therapeutic landscape of MM has evolved spectacularly over the past decades with 5-year median survival over 50%, most of these patients relapse eventually. The widely recognized therapeutic approaches include chemotherapy, radiation, stem cell transplant, and monoclonal antibody therapy. Former studies have implied that the proliferation, survival, migration and drug resistance of MM cells are in association with the activation of several signaling pathways. In this review, we intended to focus on the major signaling pathways such as PI3K/Akt/mTOR, Ras/Raf/MEK/MAPK, JAK/STAT, NF-kappa B, Wnt/beta-catenin, and RANK/RANKL/OPG, that contribute to the pathogenesis of the MM and the therapeutic approaches developed to target them. (C) 2017 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据